R Liraglutide also protects against the effects of oxidized LDL by downregulating lectin-like ox-LDL receptor-1(LOX-1) expression thus inhibiting LOX-1- mediated oxidative stress and inflammation [68]
J Cell Biol 1987
Acting as incretin mimetics, they enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety, addressing several core abnormalities in T2DM pathophysiology ( Since the approval of exenatide in 2005, the GLP-1 RA class has expanded to include liraglutide, semaglutide, dulaglutide, and lixisenatide, each differing in half-life, route of administration, and molecular structure ( Pancreatic cancer has drawn particular scrutiny due to its high fatality rate and some early observational reports suggesting elevated risk with incretin-based therapies ( Given the expanding use of GLP-1 RAs in populations already at elevated risk for gastrointestinal malignancies, there is a clear need for a comprehensive synthesis of high-quality evidence ( 2 Materials and methods 2.1 Search strategy and data sources The systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines (Supplementary Table S1
The good news is that these side effects typically diminish as the body adjusts, especially when the titration schedule is followed properly
